WO2003039468B1 - Antimnemonic therapy for hypermemory syndromes - Google Patents

Antimnemonic therapy for hypermemory syndromes

Info

Publication number
WO2003039468B1
WO2003039468B1 PCT/US2002/035524 US0235524W WO2003039468B1 WO 2003039468 B1 WO2003039468 B1 WO 2003039468B1 US 0235524 W US0235524 W US 0235524W WO 2003039468 B1 WO2003039468 B1 WO 2003039468B1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
method
disorder
cue
drug
antimnemonic
Prior art date
Application number
PCT/US2002/035524
Other languages
French (fr)
Other versions
WO2003039468A3 (en )
WO2003039468A2 (en )
Inventor
John L Haracz
Original Assignee
John L Haracz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles

Abstract

The present invention relates to antimnemonic therapy for the treatment of behaviroal disorders such as addiction, obsessive-compulsive disorder, Tourette's Syndrome, post-traumatic stress disorder (PTSD), bipolar disorder, depression, schizophrenia, anxiety disorders and personality disorders. Antimnemonic therapy may involve cue- or psychotherapy-induced reactivation of memories in combination with the administration of antimnemonic drugs.

Claims

23AMENDED CLAIMS[received by the International Bureau on 18 August 2003 (18.08.2003) original claims 1-38 replaced by amended claims 1-38 (4 pages)]
1. A method of treating a behavioral disorder, comprising:
(a) presenting a cue associated with said disorder to a patient; and
(b) administering an antimnemonic drug to the patient, said steps (a) and (b) being performed in either order.
2. The method of claim 1 , further including repeating steps (a) and (b) as needed to alleviate symptoms of said disorder.
3. The method of claim 1 wherein said cue is at least one of a visual, olfactory, aural, tactile, or gustatory cue.
4. The method of claim 1 wherein said cue is presented in a clinical environment.
5. The method of claim 1 wherein said cue is part of the patient's natural environment outside of a clinic.
6. The method of claim 1 wherein said behavioral disorder is a hypermcmory disorder.
7. The method of claim 6 wherein said hypermemory disorder is selected from the group consisting of addiction, obsessive-compulsive disorder, Tourette's syndrome, post-traumatic stress disorder (PTSD), bipolar disorder, depression, schizophrenia, anxiety disorders, and personality disorders.
8. The method of claim 7 wherein said hypermemory disorder is addiction.
9. The method of claim 1 wherein said antimnemonic drug is selected from the group consisting of benzodiazepines, NMDA-rcceptor antagonists, gmcocorticoid receptor antagonists, α2-adrenoceptor agonists, β-adrenoceptor antagonists, muscarinic cholinergic antagonists, protein kinase A inhibitors, protein kinase C inhibitors, calcium/calmodulin dependent kinase inhibitors, mitogen-activated protein kinase kinase inhibitors, cyclic adenosine monophosphate response element binding protein inhibitors, nitric oxide synthase inhibitors, and GABA receptor agonists.
10. The method of claim 1 wherein said .mtimnemonic drug is selected from the group consisting of memantine, muscimol, clonidine, metoprolol, atropine, ecopipam, sulpiride, haloperidol, 7-nitroindazole, benztropine, scopolamine, propranolol, deχtromethorphan, midazolam, and lorazepam.
11. The method of claim 10 wherein said antimnemonic drug is memantine.
12. The method of claim 11 wherem said memantine is administered at a dose of between 0.1 and 5 mg/day.
13. The method of claim 1 wherein said antimnemonic drug is administered by a clinician.
14. The method of claim 1 wherein said antimnemonic drug is self-administered by said patient,
15. The method of claim 1 wherein said antimnemonic drug is administered within five hours following said presenting of a cue.
16. The method of claim 15 wherein said antimnemonic drug is administered within thirty minutes following said presenting of a cue.
17. The method of claim 1 wherein said antimnemonic drug is administered up to one hour prior to said presenting of a cue.
18. A method of treating a behavioral disorder, comprising;
(a) reactivating a memory associated with said disorder in a patient; and 25
(b) administering an antimnemonic drug to said patient, said steps (a) and (b) being performed in either order.
19. The method of claim 18, further including repeating said steps (a) and (b) as needed Lo alleviate symptoms or to maintain symptoms in an alleviated state.
20. The method of claim 18 wherein said reactivating is triggered by presenting said patient with a cue associated with said disorder.
21. The method of claim 20 wherein said cue is at least one of a visual, olfactory, aural, tactile, or gustatory cue.
22. The method of claim 18 wherein said reactivating is triggered by psychotherapy.
23. The method of claim 18 wherein said reactivating is triggered by homework.
24. The method of claim 18 wherein said reactivating occurs in a non-clinical environment.
25. The method of claim 18 wherein said behavioral disorder is a hypermemory disorder.
26. The method of claim 25 wherein said hypermemory disorder is a behavioral disorder included in a reward-deficiency syndrome.
27, The method of claim 25 wherein said hypermemory disorder is an addiction.
28. A method of treating an addiction, comprising:
(a) exposing a patient to a cue or cues associated with said addiction;
(b) administering an antimnemonic drug to said patient, said steps (a) and (b) being performed in either order.
29. The method of claim 28 wherein said addiction is selected from the group consistmg 26
of addiction to drugs, gambling, food, sex, thrill-seeking, violence, political power, money, and computer technology.
30. The method of claim 28 wherein said addiction is to a drug.
31. The method of claim 30 wherein said addiction is to alcohol.
32. The method of claim 31 wherein said cue comprises exposure to the smell of alcoholic beverages.
33. The method of claim 30 wherein said drug is selected from the group consisting of alcohol, cocaine, nicotine, Cannabis, an opiate, and an opiate derivative.
34. The method of claim 30 wherein said addiction is to nicotine.
35, The method of claim 34 wherein said cue comprises exposure to cigarette smoke.
36. The method of claim 30 wherein said addiction is to cocaine.
37. The method of claim 36 wherein said cue comprises exposure to a smell of burning baking soda.
38. The method of claim 30 wherein said exposing said patient to a cue comprises exposing the patient to a drug-related stimulus selected from the group consisting of audiotapes, videotapes, actors performing simulated drug administration rituals, drug paraphernalia, and photographs of drug paraphernalia.
PCT/US2002/035524 2001-11-06 2002-11-05 Antimnemonic therapy for hypermemory syndromes WO2003039468B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US33271301 true 2001-11-06 2001-11-06
US60/332,713 2001-11-06

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2465869 CA2465869A1 (en) 2001-11-06 2002-11-05 Antimnemonic therapy for hypermemory syndromes

Publications (3)

Publication Number Publication Date
WO2003039468A2 true WO2003039468A2 (en) 2003-05-15
WO2003039468A3 true WO2003039468A3 (en) 2003-10-23
WO2003039468B1 true true WO2003039468B1 (en) 2003-11-27

Family

ID=23299527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035524 WO2003039468B1 (en) 2001-11-06 2002-11-05 Antimnemonic therapy for hypermemory syndromes

Country Status (2)

Country Link
CA (1) CA2465869A1 (en)
WO (1) WO2003039468B1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8118722B2 (en) 2003-03-07 2012-02-21 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
US7153256B2 (en) 2003-03-07 2006-12-26 Neuronetics, Inc. Reducing discomfort caused by electrical stimulation
EP1732530A1 (en) * 2004-03-03 2006-12-20 Merz Pharma GmbH & Co.KGaA 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
US7601115B2 (en) 2004-05-24 2009-10-13 Neuronetics, Inc. Seizure therapy method and apparatus
ES2367868T3 (en) * 2004-09-20 2011-11-10 Mount Sinai School Of Medicine Use of memantine (Namenda) to treat autism, compulsiveness and impulsivity.
US7857746B2 (en) 2004-10-29 2010-12-28 Nueronetics, Inc. System and method to reduce discomfort using nerve stimulation
US7396326B2 (en) 2005-05-17 2008-07-08 Neuronetics, Inc. Ferrofluidic cooling and acoustical noise reduction in magnetic stimulators
US7824324B2 (en) 2005-07-27 2010-11-02 Neuronetics, Inc. Magnetic core for medical procedures
EP2073813A2 (en) * 2006-10-10 2009-07-01 The University of Chicago Composition s comprising a benzodiazepine, an alcohol aversive agent and an abuse aversive agent
US20110046120A1 (en) * 2006-10-26 2011-02-24 Mclean Hospital Corporation Treatment of impulse control disorders
EP2872145A4 (en) * 2012-07-12 2015-12-02 Psyadon Pharmaceuticals Inc Fused benzazepines for treatment of tourette's syndrome
WO2016061320A3 (en) * 2014-10-15 2016-09-29 Rowan University Timber therapy for post-traumatic stress disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112487C (en) * 1991-06-26 2003-04-15 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
US5863934A (en) * 1995-09-21 1999-01-26 Amy F. T. Arnsten Use of lofexidine in the treatment of behavioral disorders

Also Published As

Publication number Publication date Type
WO2003039468A3 (en) 2003-10-23 application
CA2465869A1 (en) 2003-05-15 application
WO2003039468A2 (en) 2003-05-15 application

Similar Documents

Publication Publication Date Title
Grados et al. Pharmacotherapy in children and adolescents with obsessive-compulsive disorder.
WO2006105063A1 (en) Heterobicylic inhibitors of tgfbeta
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2004110368A3 (en) Combination therapy for the treatment of hypertension
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
WO2005007142A3 (en) Liquid compositions comprising formoterol
WO2003057144A3 (en) Change inhibitors of dipeptidyl peptidase iv
DE20205979U1 (en) Component for the production of Beeteinfassungen and boundaries in gardens and in road (curb)
WO2003078431A8 (en) Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
WO2006048449A3 (en) Mc4r selective peptides and their use in the treatment of obesity
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2006028996A3 (en) Emulsan-alginate microspheres and methods of use thereof
WO2006012504A3 (en) Compounds and methods for treatment of thrombosis
WO2003083041A8 (en) Cripto-specific antibodies
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
WO2001028591A3 (en) Injection vehicle for polymer-based formulations
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
Buttram Shaken baby syndrome (SBS): general commentary
WO2003060071A3 (en) Albumin fusion proteins
Orlov Person-centered approach in psychology, mental therapy, education and politics (towards a 100-th anniversary of C. Rogers)
WO2006015060A3 (en) Isoindoline compounds and methods of their use
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Free format text: 20030818

WWE Wipo information: entry into national phase

Ref document number: 2465869

Country of ref document: CA

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP